Headline
The latest stories from AHA Today.
Community investments help foster the social and physical environments that support communities’ long-term health. In this first episode in a series
A replay is now available of the Nov. 8 AHA/American Academy of Pediatrics/Children’s Hospital Association webinar on vaccinating pediatric patients against COVID-19. The webinar offers insights, resources and lessons learned to assist pediatricians and hospitals in working with parents and…
The Centers for Medicare & Medicaid Services will host a Nov. 10 call on its recent interim final rule requiring COVID-19 vaccinations for workers in most health care settings that participate in the Medicare and Medicaid programs, including hospitals and health systems.
The Health Resources and Services Administration in September gave health care providers who received more than $10,000 in Provider Relief Funds between April 30 and June 30, 2020, until Nov. 30, 2021, to comply with the original reporting requirements before recouping the funds or taking other…
The AHA and its Institute for Diversity and Health Equity are accepting applications through Nov. 19 for the 2022 Carolyn Boone Lewis Equity of Care Awards.
Employment at hospitals and health systems increased by more than 1,000 jobs in October, as U.S. jobs overall increased by 531,000, according to preliminary data released by the Bureau of Labor Statistics.
The Department of Health and Human Services’ National Healthcare Preparedness Programs Branch will discuss its draft guidelines for regional health care emergency preparedness and response systems during a Nov. 15 webinar for health care leaders.
The AHA sponsored a virtual Capitol Hill briefing Nov. 2, where hospital leaders discussed how COVID-19 accelerated longstanding health care workforce challenges, including worker shortages and mental health fatigue
A bipartisan group of 152 House members urged the secretaries of Health and Human Services, Treasury and Labor to amend the recent interim final rule known as Part II, implementing parts of the No Surprises Act, to align with the law Congress passed last year.
Pfizer unveiled the first phase 2/3 clinical trial data on its oral COVID-19 antiviral treatment, declaring its candidate to be highly effective in reducing the risk of hospitalization or death from severe COVID-19.